US FDA warns against co-administration of remdesivir and chloroquine or HCQ

The drug regulator informs that this may reduce the antiviral activity of remdesivir and lessen the effectiveness of COVID-19 treatment

The US Food and Drug Administration (USFDA) warned healthcare providers about a newly discovered potential drug interaction related to the investigational antiviral drug remdesivir, which has received emergency use authorisation for the treatment of hospitalised COVID-19 patients with severe disease.

Based on a recently completed non-clinical laboratory study, the FDA is revising the fact sheet for healthcare providers that accompanies the drug to state that co-administration of remdesivir and chloroquine phosphate or hydroxychloroquine sulfate is not recommended as it may result in reduced antiviral activity of remdesivir. The agency is not aware of instances of this reduced activity occurring in the clinical setting but is continuing to evaluate all data related to remdesivir.

In addition, the FDA revised the fact sheet for health care providers to clarify dosing and administration recommendations and to provide additional safety data and supporting data from clinical trials conducted by both the National Institutes of Health and the drug sponsor, Gilead Sciences. The fact sheet for patients and caregivers was also updated to include additional information about possible allergic reactions and to alert patients to tell their healthcare providers if they are taking chloroquine phosphate or hydroxychloroquine sulfate.

The FDA issued an emergency use authorisation (EUA) in May 2020 allowing for remdesivir to be distributed in the US and to be administered intravenously by healthcare providers, as appropriate, to treat suspected or laboratory-confirmed COVID-19 in adults and paediatric patients hospitalised with severe disease. The safety and efficacy of remdesivir for the treatment of COVID-19 continue to be evaluated, and preliminary clinical trial results have shown that on average, patients treated with remdesivir had more rapid time to recovery.

The EUA requires that fact sheets about using remdesivir in treating COVID-19 be made available to healthcare providers and to patients and caregivers. These fact sheets include information on possible side effects such as increased levels of liver enzymes, which may be a sign of inflammation or damage to cells in the liver; and allergic reactions, which may include low blood pressure, high heart rate, low heart rate, shortness of breath, wheezing, angioedema (for example, lip or tongue swelling), difficulty swallowing, rash, nausea, vomiting, sweating, shivering and respiratory distress.

chloroquine phosphateCovid-19 treatmentEUAHCQhydroxychloroquine sulfatepharma regulationspotential drug interactionremdesivirUS FDA
Comments (0)
Add Comment